These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34775206)

  • 1. Design, synthesis and structure-activity evaluation of novel 2-pyridone-based inhibitors of α-synuclein aggregation with potentially improved BBB permeability.
    Mahía A; Peña-Díaz S; Navarro S; José Galano-Frutos J; Pallarés I; Pujols J; Díaz-de-Villegas MD; Gálvez JA; Ventura S; Sancho J
    Bioorg Chem; 2021 Dec; 117():105472. PubMed ID: 34775206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
    Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.
    Singh SK; Dutta A; Modi G
    Future Med Chem; 2017 Jun; 9(10):1039-1053. PubMed ID: 28632413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of styrylaniline derivatives as novel alpha-synuclein aggregates ligands.
    Bian J; Liu YQ; He J; Lin X; Qiu CY; Yu WB; Shen Y; Zhu ZY; Ye DY; Wang J; Chu Y
    Eur J Med Chem; 2021 Dec; 226():113887. PubMed ID: 34624824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C9-Functionalized Doxycycline Analogs as Drug Candidates to Prevent Pathological α-Synuclein Aggregation and Neuroinflammation in Parkinson's Disease Degeneration.
    Rose C; Tomas-Grau RH; Zabala B; Michel PP; Brunel JM; Chehín R; Raisman-Vozari R; Ferrié L; Figadère B
    ChemMedChem; 2024 Jun; 19(12):e202300597. PubMed ID: 38526011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease.
    Vittorio S; Adornato I; Gitto R; Peña-Díaz S; Ventura S; De Luca L
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1727-1735. PubMed ID: 32924648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD).
    Shaltiel-Karyo R; Frenkel-Pinter M; Rockenstein E; Patrick C; Levy-Sakin M; Schiller A; Egoz-Matia N; Masliah E; Segal D; Gazit E
    J Biol Chem; 2013 Jun; 288(24):17579-88. PubMed ID: 23637226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olive oil tyrosols reduce α-synuclein aggregation
    Hernández-García S; García-Cano B; Martínez-Rodríguez P; Henarejos-Escudero P; Gandía-Herrero F
    Food Funct; 2024 Jul; 15(13):7214-7223. PubMed ID: 38817211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of α-synuclein fibrillization by ring-fused 2-pyridones: templation and inhibition involve oligomers with different structure.
    Horvath I; Sellstedt M; Weise C; Nordvall LM; Krishna Prasad G; Olofsson A; Larsson G; Almqvist F; Wittung-Stafshede P
    Arch Biochem Biophys; 2013 Apr; 532(2):84-90. PubMed ID: 23399432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 4-triazole phenyl amide (4-TPA) molecules: Potent promoters of α-synuclein fibril disassembly.
    Qiu C; Wei R; Bian J; Lin X; Bai T; He J; Guo X; Chu Y
    Eur J Med Chem; 2024 Jul; 273():116490. PubMed ID: 38772136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects.
    AlNajjar YT; Gabr M; ElHady AK; Salah M; Wilms G; Abadi AH; Becker W; Abdel-Halim M; Engel M
    Eur J Med Chem; 2022 Jan; 227():113911. PubMed ID: 34710745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multistep Inhibition of α-Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine.
    Perni M; Flagmeier P; Limbocker R; Cascella R; Aprile FA; Galvagnion C; Heller GT; Meisl G; Chen SW; Kumita JR; Challa PK; Kirkegaard JB; Cohen SIA; Mannini B; Barbut D; Nollen EAA; Cecchi C; Cremades N; Knowles TPJ; Chiti F; Zasloff M; Vendruscolo M; Dobson CM
    ACS Chem Biol; 2018 Aug; 13(8):2308-2319. PubMed ID: 29953201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models.
    Liu Q; Hou J; Chen X; Liu G; Zhang D; Sun H; Zhang J
    PLoS One; 2014; 9(7):e102442. PubMed ID: 25036090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Swertiamarin from Enicostemma littorale, counteracts PD associated neurotoxicity via enhancement α-synuclein suppressive genes and SKN-1/NRF-2 activation through MAPK pathway.
    Pandey T; Shukla A; Trivedi M; Khan F; Pandey R
    Bioorg Chem; 2021 Mar; 108():104655. PubMed ID: 33548732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
    Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
    Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico drug repositioning of FDA-approved drugs to predict new inhibitors for alpha-synuclein aggregation.
    Jafaripour SS; Gharaghani S; Nazarshodeh E; Haider S; Saboury AA
    Comput Biol Chem; 2020 Oct; 88():107308. PubMed ID: 32650066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new MAP-Rasagiline conjugate reduces α-synuclein inclusion formation in a cell model.
    Vale N; Alves C; Sharma V; Lázaro DF; Silva S; Gomes P; Outeiro TF
    Pharmacol Rep; 2020 Apr; 72(2):456-464. PubMed ID: 32048262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro inhibition of α-Synuclein aggregation and disaggregation of preformed fibers by polyphenol hybrids with 2-conjugated benzothiazole.
    Zhao YD; Zhang W; Xing LZ; Xu J; Shi WM; Zhang YX
    Bioorg Med Chem Lett; 2024 Jun; 105():129752. PubMed ID: 38631541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering the robustness of pyrazolo-pyridine carboxylate core structure-based compounds for inhibiting α-synuclein in transgenic C. elegans model of Synucleinopathy.
    Maqbool M; Rajvansh R; Srividya K; Hoda N
    Bioorg Med Chem; 2020 Sep; 28(17):115640. PubMed ID: 32773095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcorynoline attenuates dopaminergic neuron degeneration and α-synuclein aggregation in animal models of Parkinson's disease.
    Fu RH; Wang YC; Chen CS; Tsai RT; Liu SP; Chang WL; Lin HL; Lu CH; Wei JR; Wang ZW; Shyu WC; Lin SZ
    Neuropharmacology; 2014 Jul; 82():108-20. PubMed ID: 23973292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.